Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch
This article was originally published in The Pink Sheet Daily
Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.
You may also be interested in...
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.